Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
By P. Thuss-Patience, A. Kretzschmar, D. Bichev, T. Deist, A. Hinke, K. Breithaupt, Y. Doğan, B. Gebauer, G. Schumacher, P. Reichardt. European Journal of Cancer, 2011
602 citations recorded by the source corpus.
Subfields: Gastroenterology, Pulmonary and Respiratory Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/7693981025e73943fb43a6ffc958ba47ece341b5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Gastroenterology
In Pulmonary and Respiratory Medicine
In Surgery
Citations in the corpus
- Japanese gastric cancer treatment guidelines 2018 (5th edition) (2020, background): “Randomized trials conducted in Germany [56], Korea [57] and United Kingdom [58] revealed significant survival advantage of second-line chemotherapy (docetaxel or irinotecan) over BSC.”
- Japanese gastric cancer treatment guidelines 2014 (ver. 4) (2016, background): “Randomized trials conducted in Germany [24] and Korea [25] showed a significant survival advantage of the second-line treatment (docetaxel or irinotecan) over the best supportive care.”